Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid
The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage...To view the full article, register now.
Already a subscriber? Click here to view full article